Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment

被引：4
|
作者：
Sasse, Stephanie [1 ,2 ]
Reddemann, Katharina [3 ]
Diepstra, Arjan [4 ]
Borchmann, Sven [1 ,2 ,5 ,6 ]
Oschlies, Ilske [3 ]
Schnitter, Antje [3 ]
Engert, Andreas [1 ,2 ]
Borchmann, Peter [1 ,2 ]
Klapper, Wolfram [3 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Cologne, German Hodgkin Study Grp, Cologne, Germany
[3] Univ Kiel, Univ Hosp Schleswig Holstein, Hematopathol Sect, Dept Pathol, Kiel, Germany
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands
[5] Univ Hosp Cologne, Ctr Mol Med, Cologne, Germany
[6] Univ Cologne, Else Kroner Forsch Kolleg Cologne, Cologne, Germany
来源：
HAEMATOLOGICA | 2019年 / 104卷 / 01期
关键词：
D O I：
10.3324/haematol.2018.207829
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E45 / E46
页数：2
相关论文
共 50 条
  • [1] Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
    Sasse, Stephanie
    Reddemann, Katharina
    Diepstra, Arjan
    Oschlies, Ilske
    Schnitter, Antje
    Borchmann, Sven
    Engert, Andreas
    Borchmann, Peter
    Klapper, Wolfram
    HAEMATOLOGICA, 2019, 104 (01) : E21 - E24
  • [2] Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma
    Manson, Guillaume
    Brice, Pauline
    Herbaux, Charles
    Silva, Maria
    Bouabdallah, Krimo
    Deau-Fisher, Benedicte
    Bouteloup, Juliette
    de Collela, Jean Marc Schiano
    Nicolas-Virelizier, Emmanuelle
    Maerevoet, Marie
    Ghesquieres, Herve
    Bastard, Aspasia Stamatoulas
    Antier, Chloe
    Poizeau, Florence
    Dercle, Laurent
    Houot, Roch
    BLOOD, 2019, 134
  • [3] Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
    Manson, G.
    Brice, P.
    Herbaux, C.
    Silva, M. G.
    Bouabdallah, K.
    Deau, B.
    Bouteloup, J.
    Schiano, J. M.
    Nicolas-Virelizier, E.
    Maerevoet, M.
    Ghesquieres, H.
    Stamatoullas, A.
    Antier, C.
    Carlo-Stella, C.
    de Charette, M.
    Poizeau, F.
    Dercle, L.
    Houot, Roch
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (04) : 1144 - 1153
  • [4] Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
    G. Manson
    P. Brice
    C. Herbaux
    M. G. Silva
    K. Bouabdallah
    B. Deau
    J. Bouteloup
    J. M. Schiano
    E. Nicolas-Virelizier
    M. Maerevoet
    H. Ghesquieres
    A. Stamatoullas
    C. Antier
    C. Carlo-Stella
    M. de Charette
    F. Poizeau
    L. Dercle
    Roch Houot
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 1144 - 1153
  • [5] Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
    G. Manson
    P. Brice
    C. Herbaux
    M. G. Silva
    K. Bouabdallah
    B. Deau
    J. Bouteloup
    J. M. Schiano
    E. Nicolas-Virelizier
    M. Maerevoet
    H. Ghesquieres
    A. Stamatoullas
    C. Antier
    C. Carlo-Stella
    M. de Charette
    F. Poizeau
    L. Dercle
    Roch Houot
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 1699 - 1700
  • [6] Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy
    Taylor, Joseph G.
    Clear, Andrew
    Calaminici, Maria
    Gribben, John G.
    HAEMATOLOGICA, 2019, 104 (01) : E42 - E44
  • [7] Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
    Manson, Guillaume
    Brice, Pauline
    Herbaux, Charles
    Bouabdallah, Kamal
    Antier, Chloe
    Poizeau, Florence
    Dercle, Laurent
    Houot, Roch
    HAEMATOLOGICA, 2020, 105 (11) : 2664 - 2666
  • [8] Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma (vol 48, pg 1144, 2021)
    Manson, G.
    Brice, P.
    Herbaux, C.
    Silva, M. G.
    Bouabdallah, K.
    Deau, B.
    Bouteloup, J.
    Schiano, J. M.
    Nicolas-Virelizier, E.
    Maerevoet, M.
    Ghesquieres, H.
    Stamatoullas, A.
    Antier, C.
    Carlo-Stella, C.
    de Charette, M.
    Poizeau, F.
    Dercle, L.
    Houot, Roch
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (05) : 1699 - 1700
  • [9] Programmed Cell Death Ligand 1 (PD-L1) Expression in the Follicular Lymphoma Microenvironment
    Wong, Jerry T.
    Ameri, Maryam D.
    Siaghani, Parwiz
    Cantu, David
    Chen, Yuan Yuan
    Song, Joo
    Weisenburger, Dennis D.
    Kim, Young
    LABORATORY INVESTIGATION, 2017, 97 : 386A - 386A
  • [10] Programmed Cell Death Ligand 1 (PD-L1) Expression in the Follicular Lymphoma Microenvironment
    Wong, Jerry T.
    Ameri, Maryam D.
    Siaghani, Parwiz
    Cantu, David
    Chen, Yuan Yuan
    Song, Joo
    Weisenburger, Dennis D.
    Kim, Young
    MODERN PATHOLOGY, 2017, 30 : 386A - 386A
12345